Posted by Michael Wonder on 09 Apr 2018
Health Canada approves Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small-cell lung cancer
9 April 2018 - Tecentriq provides a new cancer immunotherapy option for Canadians living with the difficult disease.
Roche Canada announced today that Health Canada has approved Tecentriq (atezolizumab) as a monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy.
Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving Tecentriq.
